SA Editor Douglas W. House
Healthcare, Biotech, special situations, event-driven, growth

Organovo: Modest Expectations For The Liver Tox Assay

Few companies in the micro cap arena have garnered as much attention as Organovo (NYSEMKT:ONVO). Since its reverse merger in February 2012, thirty-nine articles have been published on Seeking Alpha. Today, almost 13,000 SA subscribers receive email alerts on the company. In a list of biotech stocks with market caps between $500M and $1B with a relative strength rating of at least 80 (per IBD), ONVO is the most-followed firm by a factor of four.

Anyone who is even casually familiar with the company knows that its long-term value proposition in regenerative medicine, tissue engineering in particular, is the reason why. What's not to like? The ability to print fully functioning replacement organs and tissues is such a...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details